Information Provided By: 
Fly News Breaks for September 21, 2018
NVAX
Sep 21, 2018 | 05:44 EDT
JPMorgan analyst Eric Joseph double upgraded Novavax to Overweight from Underweight saying the risk/reward is favorable into the Q1 of 2019 Prepare trial data, which is assessing the efficacy of the company's RSV F Vaccine for infants via maternal immunization. The analyst believes the shares can hit a range of $2.00 to $2.25. Novavax closed yesterday up 4c to $1.47.
News For NVAX From the Last 2 Days
There are no results for your query NVAX
